Laurus Labs Ltd
Laurus Labs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.
From Laurus Labs Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand.
- CDMO revenues are projected to grow to 50% of total sales by FY2030, indicating significant expansion in this segment.
- The Affordable Medicines division (formerly Generics) showed strong 18% growth in FY26, with steady business outlook.
- Fluctuations quarter-to-quarter possible, but overall growth momentum is expected to be maintained, especially in CDMO.
- New fermentation and formulation capacities coming online will support volume expansion.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).
- A new greenfield capex of 500 acres in Atchutapuram is planned; more details to be shared next quarter (Page 17).
- Capex increased from INR 1,000 crores annually to INR 1,500 crores annually, reflecting growth and with good visibility into product and customer demand (Page 16).
- Overall capex guidance is around INR 3,000 crores over the next 2 years, up from earlier INR1,000 crores, aligned with prospects and capacity needs (Page 14).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Laurus Labs has a strong order book for the next year, ensuring continued growth.
- The CDMO pipeline is robust with several late-stage programs, though exact phase-wise split or detailed numbers are not disclosed.
- Visibility exists for commercialization of some CDMO programs in FY '27, but due to clinical uncertainties, exact timing is hard to predict.
- Orders are diversified across multiple products, minimizing concentration and destocking risks.
2 more points management made on order book & pipeline
Laurus Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Laurus Labs Ltd Q4 FY26 results?
Laurus Labs expects continued strong growth in the next year, reflecting a robust order book and visible demand. Laurus Labs expects strong growth in CDMO segment with good year-on-year growth in FY '27, despite possible quarter-to-quarter lumpiness.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 96.6 with a market cap of ₹105,577 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
Laurus Labs is investing in new modalities including cell culture, precision fermentation, enzymes, biocatalysis, cell therapy, gene therapy, and ADCs as a strategic focus (Page 17).
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.